Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

656
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
656
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

1.1K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

793
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
793
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival estimates and their predictors in genetic frontotemporal dementia: an international, retrospective, cohort study.

The Lancet. Neurology·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Predicting progression from subjective cognitive decline to dementia using different neuropsychological criteria: A longitudinal study.

Archives of gerontology and geriatrics·2026
Same author

Peripheral microRNA signature in genetic frontotemporal dementia-findings from the GENFI initiative.

GeroScience·2026
Same author

Coping Strategies Used by Caregivers of Patients With Mild Cognitive Impairment due to Alzheimer's Disease - A Longitudinal Study.

Journal of geriatric psychiatry and neurology·2026
Same author

Composite grey matter fingerprints for genetic frontotemporal dementia.

Journal of neurology, neurosurgery, and psychiatry·2026

Related Experiment Video

Updated: Mar 15, 2026

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K

Delay discounting in mild cognitive impairment.

Sara Coelho1, Manuela Guerreiro1, Catarina Chester1

  • 1a Institute of Molecular Medicine and Faculty of Medicine , University of Lisbon , Lisbon , Portugal.

Journal of Clinical and Experimental Neuropsychology
|September 13, 2016
PubMed
Summary

Mild cognitive impairment (MCI) patients show similar temporal discounting abilities to healthy individuals. Memory deficits do not significantly impact decision-making regarding immediate versus delayed rewards.

Keywords:
Decision-makingDelay discountingMemoryMild cognitive impairmentTemporal preferences

More Related Videos

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.9K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Related Experiment Videos

Last Updated: Mar 15, 2026

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.9K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Area of Science:

  • Neuroscience
  • Cognitive Psychology
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) is associated with potential decision-making deficits.
  • Temporal discounting, preferring immediate over delayed rewards, may underlie these deficits.

Purpose of the Study:

  • To evaluate intertemporal preferences in MCI patients compared to healthy controls.
  • To determine if temporal discounting is affected by mild cognitive impairment.

Main Methods:

  • Fifty-five MCI patients and 57 healthy controls completed a delay discounting questionnaire.
  • Key parameters assessed included hyperbolic discounting (k), percentage of choices for delayed rewards (%LL), and response consistency (Acc).

Main Results:

  • No significant differences were observed between MCI patients and controls in delay discounting parameters (k, %LL) across small, medium, and large reward sizes.
  • Response consistency (Acc) also did not differ between the two groups.

Conclusions:

  • MCI patients exhibit comparable performance to healthy controls on delay discounting tasks.
  • Memory deficits in MCI do not appear to substantially alter intertemporal decision-making preferences.